Development of an AlphaLISA protein-protein interaction assay to screen for re-purposed drugs as targeted disruptors

In this application note, a protein-protein interaction assay between angiotensin-converting enzyme 2 (ACE2) and the SAR-CoV-2 Spike Protein (S1) Receptor Binding Domain (RBD) was developed. This provides an example of how improved assay and microplate reader technologies can be leveraged to develop new screens to improve our ability to respond to emerging diseases.